Biblio
Export 924 results:
Author Title Type [ Year] Filters: First Letter Of Last Name is F [Clear All Filters]
“The APOE Gene is Differentially Methylated in Alzheimer's Disease.”, J Alzheimers Dis, 2015.
, “A Blood-Based, 7-Metabolite Signature for the Early Diagnosis of Alzheimer's Disease.”, J Alzheimers Dis, 2015.
, “A Blood-Based, 7-Metabolite Signature for the Early Diagnosis of Alzheimer's Disease.”, J Alzheimers Dis, 2015.
, “A Blood-Based, 7-Metabolite Signature for the Early Diagnosis of Alzheimer's Disease.”, J Alzheimers Dis, 2015.
, “Buccal Cell Cytokeratin 14 Correlates with Multiple Blood Biomarkers of Alzheimer's Disease Risk.”, J Alzheimers Dis, vol. 48, no. 2, pp. 443-52, 2015.
, “Buccal Cell Cytokeratin 14 Correlates with Multiple Blood Biomarkers of Alzheimer's Disease Risk.”, J Alzheimers Dis, vol. 48, no. 2, pp. 443-52, 2015.
, “Cognitive Effects of Soy Isoflavones in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 47, no. 4, pp. 1009-19, 2015.
, “Comprehensive Gene- and Pathway-Based Analysis of Depressive Symptoms in Older Adults.”, J Alzheimers Dis, 2015.
, “Comprehensive Gene- and Pathway-Based Analysis of Depressive Symptoms in Older Adults.”, J Alzheimers Dis, 2015.
, “The Continuing Failure of Bexarotene in Alzheimer's Disease Mice.”, J Alzheimers Dis, 2015.
, “Depression and Suicidal Ideation During Two Psychosocial Treatments in Older Adults with Major Depression and Dementia.”, J Alzheimers Dis, vol. 48, no. 2, pp. 453-62, 2015.
, “The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer's Disease.”, J Alzheimers Dis, 2015.
, “The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer's Disease.”, J Alzheimers Dis, 2015.
, “Mapping the Progression of Atrophy in Early- and Late-Onset Alzheimer's Disease.”, J Alzheimers Dis, 2015.
, , “Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.”, Lancet Neurol, vol. 13, no. 6, pp. 614-29, 2014.
, “Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.”, Lancet Neurol, vol. 13, no. 6, pp. 614-29, 2014.
, “Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.”, Lancet Neurol, vol. 13, no. 6, pp. 614-29, 2014.
, “Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
, “Plasma phospholipids identify antecedent memory impairment in older adults.”, Nat Med, vol. 20, no. 4, pp. 415-8, 2014.
, “Plasma phospholipids identify antecedent memory impairment in older adults.”, Nat Med, vol. 20, no. 4, pp. 415-8, 2014.
, “Plasma phospholipids identify antecedent memory impairment in older adults.”, Nat Med, vol. 20, no. 4, pp. 415-8, 2014.
, “Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 322-33, 2014.
, “Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 322-33, 2014.
, “Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies.”, Ann Neurol, vol. 73, no. 4, pp. 449-58, 2013.
,